Rita Johnson-Greene is an accomplished international healthcare executive leader with over 20 years of progressive experience. Rita has worked at several world-class organizations and her experience includes, product launch, commercial operations, corporate finance, sales leadership, market access & payer reimbursement, ultrarare disease, international business, financial planning and reporting, fleet management, contracting, manufacturing, field force optimization and resource allocation. Rita has launched three of the five gene therapies currently marketed in the US, including Luxturna, the first FDA approved gene therapy.

Rita currently serves as an Executive Board member of Public Health Management Corporation (PHMC), which is a non-profit that serves ~350,000 clients annually. PHMC has 70 locations (including hospitals) and provides more than 350 programs. Rita also serves on the Board of GirlTrek, a global African American Women’s Health Movement.

Rita is currently the Chief Operating Officer at the Alliance for Regenerative Medicine (ARM), which is the leading international advocacy organization representing the engineered cell therapy and genetic medicines sector. Rita oversees multiple functions, including membership, finance, programming, and people and culture. She is also responsible for ARM’s geographic expansion initiative.